MEREO BIOPHARMA GROUP PLC (MREO) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -388.66×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | -388.66× | Operating income ÷ reported interest expense. $-34.20M ÷ $88.00K ≈ -388.66× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 15.02M USD | Research and Development Expense |
| Revenue | 0.00 USD | |
| Stock-based compensation | 6.18M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -34.20M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 88.00K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.02M | $0.00 | $6.18M | $-34.20M | $88.00K | (m) | (m) | -388.66× | Reported |
| 2026-03-31 | $18.58M | (m) | $6.92M | $-37.67M | $95.00K | (m) | (m) | -396.54× | Reported |
| 2025-12-31 | $17.77M | $500.00K | $7.60M | $-40.11M | $255.00K | 3553.20% | 1519.60% | -157.28× | Reported |
| 2025-09-30 | $22.39M | $500.00K | $7.57M | $-46.99M | $607.00K | 4478.80% | 1514.00% | -77.42× | Reported |
| 2025-06-30 | $21.29M | $500.00K | $7.59M | $-46.35M | $933.00K | 4258.80% | 1519.00% | -49.68× | Reported |
| 2025-03-31 | $20.87M | (m) | $7.62M | $-48.67M | $1.24M | (m) | (m) | -39.25× | Reported |
| 2024-12-31 | $20.93M | $0.00 | $7.39M | $-47.36M | $1.37M | (m) | (m) | -34.57× | Reported |
| 2024-09-30 | $16.91M | $1.00M | $6.69M | $-39.22M | $1.35M | 1691.30% | 669.00% | -29.09× | Reported |
| 2024-06-30 | $17.34M | $1.00M | $6.49M | $-38.91M | $1.69M | 1733.80% | 648.60% | -22.98× | Reported |
| 2024-03-31 | $16.11M | $10.00M | $5.34M | $-26.91M | $2.39M | 161.05% | 53.39% | -11.25× | Reported |
| 2023-12-31 | $17.42M | $10.00M | $4.92M | $-28.42M | $2.88M | 174.18% | 49.24% | -9.86× | Reported |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $29.46M | $0.00 | $4.77M | $-54.43M | $4.17M | (m) | (m) | -13.04× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |